Corticosteroids not linked with reduced risk of death for children with bacterial meningitis

In adults, the use of corticosteroids (synthetic steroids used to reduce inflammation) in addition to primary therapy for bacterial meningitis reduces mortality, although in children the potential benefit of steroids remains unclear, with studies yielding mixed results, according to background information in the article.

Jillian Mongelluzzo, B.A., of the Children’s Hospital of Philadelphia, and colleagues conducted a study to determine the effect of adjuvant (supplemental) corticosteroid therapy on death and length of hospitalization in children with bacterial meningitis. The study included 2,780 children treated for bacterial meningitis, with data from the Pediatric Health Information System, a database containing information from 27 tertiary care children’s hospitals located in 18 U.S. states and the District of Columbia. The median (midpoint) age was 9 months; 57 percent of the patients were males. Streptococcus pneumoniae was the most commonly identified cause of meningitis. Adjuvant corticosteroids were administered to 248 children (8.9 percent).

The overall rate of death was 4.2 percent; the cumulative rates of death were 2.2 percent and 3.1 percent at 7 days and 28 days, respectively, after admission. There were 15 deaths (6.0 percent) in children who received corticosteroids and 102 deaths (4.0 percent) in children who did not receive corticosteroids. Additional analysis indicated the difference in time to death between the two groups was not statistically significant, and that adjuvant corticosteroids were not associated with reducing the risk of death in any age category.

The overall median length of stay was 11 days, with the median length of stay for children who received corticosteroids being 12 days, and the median length of stay for the children who did not receive corticosteroids being 10 days. The unadjusted difference in time to hospital discharge was not statistically significant. Length of hospital stay, analyzed as time to hospital discharge, was not associated with the administration of adjuvant corticosteroids for any age group.

“Our study results of no difference in mortality in children who received or did not receive corticosteroid therapy may differ from results of studies of adults for several reasons. First, adults may have different predisposing factors for meningitis or a different inflammatory response, either of which may alter the course of disease compared with children. Second, the case fatality rate in pneumococcal meningitis in children is lower in comparison with the case fatality rate in adults with pneumococcal meningitis (4.2 percent vs. 34 percent, respectively). Our study could have been underpowered to determine a difference in mortality when case fatality rates are low in children with bacterial meningitis,” the authors write.

“… adjuvant corticosteroid use in the treatment of bacterial meningitis appears to be increasing. A randomized trial is warranted to explore the possible benefit of adjuvant corticosteroid therapy on both morbidity and mortality in children with bacterial meningitis before such corticosteroid use becomes routine,” the researchers conclude.

Source: JAMA and Archives Journals

Steroids provide no survival benefit for children with bacterial meningitis
Corticosteroids given to children who are hospitalized for bacterial meningitis do not provide a benefit in survival or in reduced hospital stays, according to a large multicenter study by pediatric researchers. This finding stands in contrast to previous studies in hospitalized adults, for which corticosteroids dramatically reduced mortality.
Vaccinated infants well-protected against severe pneumococcal infection in Norway
In 2006, a pneumococcal vaccine (Prevenar®) was introduced in the childhood vaccination programme in Norway. Two years later, the experiences have been published in the journal Vaccine. The results show a strong decline in serious pneumococcal infections among young children.
New research reveals ultraviolet light therapy is as beneficial for darker skin as lighter skin
An analysis of more than 100 patients has confirmed for the first time that darker-skinned patients benefit as those with lighter skin when given light therapy for morphea and related diseases, UT Southwestern Medical Center researchers show.
Effects of meningitis C jab may wear off
One in five 11–13 year olds appear to have low antibodies against meningitis C after being immunised as young children, suggests an Oxford University study published in the British Medical Journal.
Despite vaccine, public should not get complacent about pneumococcal disease
Although the childhood pneumococcal conjugate vaccine has been a boon in reducing the incidence invasive pneumococcal disease (IPD), the public and the medical community must not get complacent, as non-vaccine strains, some resistant to antibiotics, are on the rise, say scientists at a meeting today in Boston.
Incidence of group B strep has decreased among newborns, but has increased among adults
Group B streptococcus, a major cause of serious infections, declined about 25 percent among infants younger than 7 days from 1999 to 2005, but increased nearly 50 percent among persons 15 to 64 years old, according to a study in the May 7 issue of JAMA.
How much progress has there been in vaccinating against Hib in the Americas?
The bacterium Haemophilus influenzae type b (Hib) causes at least 3 million cases of severe disease each year, and about 400,000 children die annually due to pneumonia or meningitis caused by Hib.
Gestational age not only factor in outcome of severely premature healthy babies
Researchers at The University of Texas Medical School at Houston say a crucial decision on whether to give intensive care to extremely premature infants should not be solely based on the infant’s gestational age.

Corticosteroids not linked with reduced risk of death for children with bacterial meningitis

Related stories:

News discussion: